

# Alexander Guminski

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/8943718/publications.pdf>

Version: 2024-02-01

33  
papers

2,988  
citations

759233

12  
h-index

501196

28  
g-index

33  
all docs

33  
docs citations

33  
times ranked

4570  
citing authors

#	ARTICLE	IF	CITATIONS
1	Outcome of patient with myasthenia gravis with the use of immunotherapy in metastatic Merkel cell carcinoma. <i>Oxford Medical Case Reports</i> , 2022, 2022, omac012.	0.4	1
2	Second primary malignancies in chronic lymphocytic leukaemia: Skin, solid organ, haematological and Richter's syndrome. <i>EJHaem</i> , 2022, 3, 129-138.	1.0	10
3	Succinate dehydrogenase-deficient gastrointestinal stromal tumor: from diagnostic dilemma to novel personalised therapy in 2 case reports. <i>Translational Cancer Research</i> , 2021, 10, 0-0.	1.0	6
4	Abstract CT225: Phase 1 trial of SQ3370 in solid tumors. , 2021, , .		0
5	Integrated analysis of a phase 2 study of cemiplimab in advanced cutaneous squamous cell carcinoma: extended follow-up of outcomes and quality of life analysis. , 2021, 9, e002757.		46
6	Key Clinical Adverse Events in Patients with Advanced Basal Cell Carcinoma Treated with Sonidegib or Vismodegib: A Post Hoc Analysis. <i>Dermatology and Therapy</i> , 2021, 11, 1839-1849.	3.0	9
7	Effects of Sonidegib Following Dose Reduction and Treatment Interruption in Patients with Advanced Basal Cell Carcinoma During 42-Month BOLT Trial. <i>Dermatology and Therapy</i> , 2021, 11, 2225-2234.	3.0	9
8	Using drug scheduling to manage adverse events associated with hedgehog pathway inhibitors for basal cell carcinoma. <i>Oncotarget</i> , 2021, 12, 2531-2540.	1.8	5
9	The changing paradigm of managing Merkel cell carcinoma in Australia: An expert commentary. <i>Asia-Pacific Journal of Clinical Oncology</i> , 2020, 16, 312-319.	1.1	13
10	Phase 2 study of cemiplimab in patients with metastatic cutaneous squamous cell carcinoma: primary analysis of fixed-dosing, long-term outcome of weight-based dosing. , 2020, 8, e000775.		113
11	Why pathologists and oncologists should know about tumour-infiltrating lymphocytes (TILs) in triple-negative breast cancer: an Australian experience of 139 cases. <i>Pathology</i> , 2020, 52, 515-521.	0.6	5
12	Decoding a mysterious morphology with molecular pathology: chondroid metaplasia in a metastatic gastrointestinal stromal tumour after imatinib therapy. <i>Pathology</i> , 2020, 52, 396-398.	0.6	2
13	Cemiplimab in locally advanced cutaneous squamous cell carcinoma: results from an open-label, phase 2, single-arm trial. <i>Lancet Oncology, The</i> , 2020, 21, 294-305.	10.7	304
14	416â€¦SQ3370â€œ001 is a multi-center open-label phase I dose-escalation study to test a novel intratumoral and systemic approach to treat advanced solid tumors. , 2020, , .		0
15	Validation of the 8th edition UICC/AJCC TNM staging system for HPV associated oropharyngeal cancer patients managed with contemporary chemo-radiotherapy. <i>BMC Cancer</i> , 2019, 19, 674.	2.6	34
16	Immunotherapy and other systemic therapies for cutaneous SCC. <i>Oral Oncology</i> , 2019, 99, 104459.	1.5	17
17	Chronic lymphocytic leukemia, skin and other second cancers. <i>Leukemia and Lymphoma</i> , 2019, 60, 3104-3106.	1.3	9
18	Neoadjuvant dabrafenib combined with trametinib for resectable, stage IIIBâ€œC, BRAFV600 mutation-positive melanoma (NeoCombi): a single-arm, open-label, single-centre, phase 2 trial. <i>Lancet Oncology, The</i> , 2019, 20, 961-971.	10.7	126

#	ARTICLE	IF	CITATIONS
19	Distinct Immune Cell Populations Define Response to Anti-PD-1 Monotherapy and Anti-PD-1/Anti-CTLA-4 Combined Therapy. <i>Cancer Cell</i> , 2019, 35, 238-255.e6.	16.8	547
20	Management of Regional Lymph Nodes in Patients with Merkel Cell Carcinoma Following a Positive Sentinel Node Biopsy: Less May be More, But is Either Enough?. <i>Annals of Surgical Oncology</i> , 2019, 26, 315-317.	1.5	4
21	Real-world experience of the feasibility and tolerability of the 2/1 dosing schedule with sunitinib in the treatment of patients with advanced renal cell carcinoma in Australia. <i>Asia-Pacific Journal of Clinical Oncology</i> , 2018, 14, e45-e49.	1.1	3
22	Advanced Renal Cell Cancer and Low-Dose Palliative Radiation Treatment: A Case of a Substantial and Sustained Treatment Response. <i>Case Reports in Oncology</i> , 2018, 11, 756-762.	0.7	3
23	Stereotactic Body Radiotherapy for Oligometastatic Prostate Cancer Detected via Prostate-specific Membrane Antigen Positron Emission Tomography. <i>European Urology Oncology</i> , 2018, 1, 531-537.	5.4	106
24	PD-1 Blockade with Cemiplimab in Advanced Cutaneous Squamous-Cell Carcinoma. <i>New England Journal of Medicine</i> , 2018, 379, 341-351.	27.0	997
25	Primary analysis of phase 2 results for cemiplimab, a human monoclonal anti-PD-1, in patients with metastatic cutaneous squamous cell carcinoma (mCSCC).. <i>Journal of Clinical Oncology</i> , 2018, 36, 9519-9519.	1.6	2
26	Survival of patients with melanoma brain metastasis treated with stereotactic radiosurgery and active systemic drug therapies. <i>European Journal of Cancer</i> , 2017, 75, 169-178.	2.8	96
27	Preliminary results from the international neoadjuvant melanoma consortium (INMC).. <i>Journal of Clinical Oncology</i> , 2017, 35, 9581-9581.	1.6	11
28	The 12-month analysis from Basal Cell Carcinoma Outcomes with LDE225 Treatment (BOLT): A phase II, randomized, double-blind study of sonidegib in patients with advanced basal cell carcinoma. <i>Journal of the American Academy of Dermatology</i> , 2016, 75, 113-125.e5.	1.2	133
29	Efficacy and safety of sonidegib in patients (pts) with locally advanced (la) or metastatic (m) basal cell carcinoma (BCC): BOLT 30-month analysis.. <i>Journal of Clinical Oncology</i> , 2016, 34, 9538-9538.	1.6	1
30	Treatment with two different doses of sonidegib in patients with locally advanced or metastatic basal cell carcinoma (BOLT): a multicentre, randomised, double-blind phase 2 trial. <i>Lancet Oncology</i> , The, 2015, 16, 716-728.	10.7	325
31	Nonmelanoma Cutaneous Head and Neck Cancer and Merkel Cell Carcinoma: Current Concepts, Advances, and Controversies. <i>Journal of Clinical Oncology</i> , 2015, 33, 3338-3345.	1.6	50
32	How important is multidisciplinary treatment of melanoma metastases?. <i>Expert Review of Dermatology</i> , 2013, 8, 339-341.	0.3	0
33	Cardiac toxicity from sunitinib: Do we need to be more vigilant?. <i>Asia-Pacific Journal of Clinical Oncology</i> , 2009, 5, 217-218.	1.1	1